Much larger numbers of UC and EC samples from LS patients will need to be analysed, and/or patient groups at increased risk of developing these cancers, such as MSH2-variant carriers for UTUCs [2] and patients presenting with post-menopausal bleeding for EC [37]. This evidence concerns the gene MSH2 and cancer.